Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Lozanski

Showing results (61-70 of 134) with videos related to

Pageof 14
Sort By:
Cancer Discovery|January 10, 2020
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic LeukemiaJennifer A Woyach, James S Blachly, Kerry A Rogers, et al.
Vaccines|November 25, 2023
Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of ProtectionKimia Sobhani, Susan Cheng, Raquel A Binder, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Neutralization and Stability of SARS-CoV-2 Omicron VariantCong Zeng, John P Evans, Panke Qu, et al.
Blood Advances|July 29, 2018
Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphomaBethany Mundy-Bosse, Nathan Denlinger, Eric McLaughlin, et al.
Cell Host & Microbe|May 8, 2022
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2John P Evans, Cong Zeng, Panke Qu, et al.
Haematologica|May 19, 2018
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34<sup>+</sup>CD123<sup>+</sup> cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donorsRajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, et al.
Blood|August 17, 2018
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Leukemia Research|September 5, 2022
Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919]Mirela Anghelina, Michelle J Naughton, Qiuhong Zhao, et al.
Vaccines|June 2, 2021
Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative DiseaseElshafa Hassan Ahmed, Eric Brooks, Shelby Sloan, et al.
Leukemia Research|July 23, 2022
Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemiaMirela Anghelina, Michelle J Naughton, Qiuhong Zhao, et al.
Pageof 14

Showing results (61-70 of 134) with videos related to

Sort By:
Pageof 14
Cancer Discovery|January 10, 2020
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic LeukemiaJennifer A Woyach, James S Blachly, Kerry A Rogers, et al.
Vaccines|November 25, 2023
Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of ProtectionKimia Sobhani, Susan Cheng, Raquel A Binder, et al.
Biorxiv : the Preprint Server for Biology|January 4, 2022
Neutralization and Stability of SARS-CoV-2 Omicron VariantCong Zeng, John P Evans, Panke Qu, et al.
Blood Advances|July 29, 2018
Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphomaBethany Mundy-Bosse, Nathan Denlinger, Eric McLaughlin, et al.
Cell Host & Microbe|May 8, 2022
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2John P Evans, Cong Zeng, Panke Qu, et al.
Haematologica|May 19, 2018
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34<sup>+</sup>CD123<sup>+</sup> cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donorsRajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, et al.
Blood|August 17, 2018
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemiaKerry A Rogers, Ying Huang, Amy S Ruppert, et al.
Leukemia Research|September 5, 2022
Corrigendum to "Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemia" [Leuk. Res. 120 (2022) 106919]Mirela Anghelina, Michelle J Naughton, Qiuhong Zhao, et al.
Vaccines|June 2, 2021
Targeted Delivery of BZLF1 to DEC205 Drives EBV-Protective Immunity in a Spontaneous Model of EBV-Driven Lymphoproliferative DiseaseElshafa Hassan Ahmed, Eric Brooks, Shelby Sloan, et al.
Leukemia Research|July 23, 2022
Patient-driven research: Initial results from a prospective health-related quality of life study performed at the request of patients living with hairy cell leukemiaMirela Anghelina, Michelle J Naughton, Qiuhong Zhao, et al.
Pageof 14